WO2006074451A3 - Molecules chimeriques ciblees pour la therapie du cancer - Google Patents

Molecules chimeriques ciblees pour la therapie du cancer Download PDF

Info

Publication number
WO2006074451A3
WO2006074451A3 PCT/US2006/000828 US2006000828W WO2006074451A3 WO 2006074451 A3 WO2006074451 A3 WO 2006074451A3 US 2006000828 W US2006000828 W US 2006000828W WO 2006074451 A3 WO2006074451 A3 WO 2006074451A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric molecules
cancer therapy
cell proliferation
moiety
targeted chimeric
Prior art date
Application number
PCT/US2006/000828
Other languages
English (en)
Other versions
WO2006074451A9 (fr
WO2006074451A2 (fr
Inventor
Michael G Rosenblum
Andrew D Ellington
Original Assignee
Res Dev Foundation
Michael G Rosenblum
Andrew D Ellington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation, Michael G Rosenblum, Andrew D Ellington filed Critical Res Dev Foundation
Priority to CA002593648A priority Critical patent/CA2593648A1/fr
Priority to AU2006203850A priority patent/AU2006203850A1/en
Priority to JP2007550561A priority patent/JP2008526889A/ja
Priority to EP06733667A priority patent/EP1846039A2/fr
Publication of WO2006074451A2 publication Critical patent/WO2006074451A2/fr
Publication of WO2006074451A3 publication Critical patent/WO2006074451A3/fr
Publication of WO2006074451A9 publication Critical patent/WO2006074451A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a trait à des molécules chimériques pour la thérapie du cancer comportant un groupe fonctionnel de ciblage et un groupe fonctionnel contre la prolifération cellulaire. Dans des modes de réalisation spécifiques, le groupe fonctionnel contre la prolifération cellulaire peut comporter un agent cytotoxique ou un facteur induisant l'apoptose. Dans des modes de réalisation particuliers, le mécanisme contre la prolifération cellulaire des molécules chimériques comportent des voies apoptotiques. Dans des modes de réalisation supplémentaires, les molécules chimériques de la présente invention assurent la sensibilité à la chimiothérapie dans une cellule qui est résistante à la chimiothérapie.
PCT/US2006/000828 2005-01-10 2006-01-10 Molecules chimeriques ciblees pour la therapie du cancer WO2006074451A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002593648A CA2593648A1 (fr) 2005-01-10 2006-01-10 Molecules chimeriques ciblees pour la therapie du cancer
AU2006203850A AU2006203850A1 (en) 2005-01-10 2006-01-10 Targeted chimeric molecules for cancer therapy
JP2007550561A JP2008526889A (ja) 2005-01-10 2006-01-10 癌治療のための標的化キメラ分子
EP06733667A EP1846039A2 (fr) 2005-01-10 2006-01-10 Molecules chimeriques ciblees pour la therapie du cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64333705P 2005-01-10 2005-01-10
US60/643,337 2005-01-10

Publications (3)

Publication Number Publication Date
WO2006074451A2 WO2006074451A2 (fr) 2006-07-13
WO2006074451A3 true WO2006074451A3 (fr) 2007-03-08
WO2006074451A9 WO2006074451A9 (fr) 2007-04-26

Family

ID=36607584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/000828 WO2006074451A2 (fr) 2005-01-10 2006-01-10 Molecules chimeriques ciblees pour la therapie du cancer

Country Status (8)

Country Link
US (1) US20060263368A1 (fr)
EP (1) EP1846039A2 (fr)
JP (1) JP2008526889A (fr)
CN (1) CN101203247A (fr)
AU (1) AU2006203850A1 (fr)
CA (1) CA2593648A1 (fr)
RU (1) RU2007130552A (fr)
WO (1) WO2006074451A2 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728541A (en) * 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
WO2008040087A1 (fr) * 2006-10-06 2008-04-10 The Walter And Eliza Hall Institute Of Medical Research Procédé de traitement et agents utiles pour ledit procédé
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008109997A1 (fr) * 2007-03-09 2008-09-18 The University Of British Columbia Ciblage de maladie à médiation de la pro-caspase-8
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CN108129573B (zh) 2007-09-21 2021-10-08 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
CA2720168C (fr) * 2008-04-04 2024-04-30 David B. Weiner Vaccins et agents immunotherapeutiques utilisant il-28 et compositions et methodes les utilisant
US20100047164A1 (en) * 2008-04-11 2010-02-25 Duke University Anti-Tumor Antibodies
ES2342529B1 (es) * 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.
KR20110086101A (ko) * 2008-10-21 2011-07-27 메르크 파텐트 게엠베하 방사선 및 면역사이토카인으로의 암 치료
EP2362783A2 (fr) 2008-10-31 2011-09-07 Biogen Idec MA Inc. Molécules ciblant light et leurs utilisations
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
WO2011020012A1 (fr) * 2009-08-14 2011-02-17 The Trustees Of The University Of Pennsylvania Défaut d'expression du tnfα et du récepteur de type 1 pour le tnfα protégeant les cellules cancéreuses d'une mort cellulaire programmée induite par le tnfα (apoptose cellulaire)
WO2011029008A2 (fr) * 2009-09-04 2011-03-10 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Corps de synthèse dirigés contre akt1
EP2483407A2 (fr) 2009-09-30 2012-08-08 President and Fellows of Harvard College Procédés de modulation de l'autophagie par la modulation de produits géniques renforçant l'autophagie
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011110932A1 (fr) 2010-03-12 2011-09-15 Council Of Scientific & Industrial Research Procédé pour la production de violacéine et son dérivé désoxyviolacéine contenant un pigment bioactif de chromobacterium sp. (mtcc 5522)
NZ603004A (en) * 2010-04-08 2014-05-30 Symansis Ltd Assay system
WO2011146862A1 (fr) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Méthodes d'induction d'une apoptose sélective
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
PL394618A1 (pl) * 2011-04-19 2012-10-22 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
US10683362B2 (en) * 2011-05-06 2020-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxin targeting mesothelin
US20130150566A1 (en) * 2011-07-06 2013-06-13 Targetpharma Laboratories (Changzhou) Co., Ltd Tumor-targeted tnf-related apoptosis-inducing ligand's variant and the application thereof
US9096840B2 (en) * 2012-10-04 2015-08-04 Research Development Foundation Serine protease molecules and therapies
EP2730289A1 (fr) * 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Nouveaux immuno-protéases
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US8808719B1 (en) 2013-03-15 2014-08-19 Marrone Bio Innovations, Inc. Use of Chromobacterium substugae formulations, compostions and compounds to modulate cornworm rootworm larvae infestation
WO2014194100A1 (fr) 2013-05-29 2014-12-04 The Regents Of The University Of California Fusions anti-cspg4 et interféron utilisables en vue du traitement de tumeurs malignes
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
JP6936934B2 (ja) * 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
CA2937750A1 (fr) * 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methodes d'activation des lymphocytes t a l'aide d'un polypeptide chimere inductible
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR101492053B1 (ko) * 2014-07-14 2015-02-11 경북대학교 산학협력단 뉴로펩티드 y를 포함하는 항암제 부작용 억제용 조성물
RU2576232C1 (ru) * 2014-10-27 2016-02-27 федеральное государственное автономное образовательное учреждение высшего образования "Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный иммунотоксин, специфичный к клеткам, экспрессирующим рецептор her2
ES2904301T3 (es) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Receptores de células T dirigidos contra Bob1 y usos de los mismos
GB201503133D0 (en) * 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
WO2016138590A1 (fr) 2015-03-03 2016-09-09 Wilfred Jefferies Modulation de l'immunité anticancéreuse à l'aide de cellules lymphoïdes innées de type 2, de l'interleukine 33 et/ou de la protéine 44 induite par l'interféron
RU2018105687A (ru) * 2015-07-16 2019-08-16 Филоджен С.П.А. Иммуноконъюгаты на основе il22
CN109311950A (zh) * 2016-03-21 2019-02-05 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
WO2017211278A1 (fr) * 2016-06-06 2017-12-14 Asclepiumm Taiwan Co., Ltd Protéines de fusion à des anticorps pour l'administration de médicaments
TW201814045A (zh) * 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
BR112019023184A2 (pt) 2017-05-12 2020-05-19 Jiangsu Hengrui Medicine Co proteína de fusão contendo o receptor de tgf-¿ e o uso farmacêutico da mesma
CN107099603A (zh) * 2017-05-31 2017-08-29 成都克里斯博生物科技有限公司 肿瘤免疫t细胞检测试剂盒和检测方法
CN112546244B (zh) * 2017-06-22 2023-07-04 密执安州立大学董事会 成纤维细胞生长因子受体2特异性肽试剂和方法
KR20200088831A (ko) * 2017-11-16 2020-07-23 티르노보 리미티드 암 치료용 irs/stat3 이중 조절제 및 항 pd-1/pd-l1 항체의 조합물
CN108676097B (zh) * 2018-05-24 2020-01-14 北京肽和生物科技有限公司 一种靶向肿瘤细胞的嵌合肽或嵌合蛋白及其应用
EP3878461A4 (fr) 2018-11-09 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. COMPOSITION PHARMACEUTIQUE À BASE D'UNE PROTÉINE DE FUSION DU RÉCEPTEUR TGF-ß ET SON UTILISATION
CN111944056B (zh) * 2020-07-15 2021-08-13 南京中医药大学 凋亡蛋白融合型抗her-2单链抗体及其制备方法和应用
US20230365653A1 (en) 2020-07-24 2023-11-16 Mabwell (shanghai) Bioscience Co., Ltd. Tgf-beta rii mutant and fusion protein thereof
CN112201344A (zh) * 2020-10-09 2021-01-08 郑州大学第一附属医院 唾液代谢标志物在早期诊断口腔扁平苔藓的应用
CN113880917B (zh) * 2021-10-22 2023-04-28 中国药科大学 几种肿瘤高亲和肽及其应用
CN114404429B (zh) * 2021-11-30 2023-06-30 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069886A2 (fr) * 2001-02-12 2002-09-12 Research Development Foundation Proteines modifiees, toxines mises au point et procedes de fabrication de celles-ci
WO2003007889A2 (fr) * 2001-07-17 2003-01-30 Research Development Foundation Agents therapeutiques contenant des proteines pro-apoptotiques
WO2004096271A1 (fr) * 2003-04-30 2004-11-11 Uwe Zangemeister-Wittke Procedes de traitement de cancer mettant en oeuvre une immunotoxine
US20050163774A1 (en) * 1992-04-10 2005-07-28 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5519119A (en) * 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
JPH05255393A (ja) * 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd ポリペプチド
CA2055168A1 (fr) * 1990-11-21 1992-05-22 Walter Fiers Muteines de tnf
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5606023A (en) * 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163774A1 (en) * 1992-04-10 2005-07-28 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
WO2002069886A2 (fr) * 2001-02-12 2002-09-12 Research Development Foundation Proteines modifiees, toxines mises au point et procedes de fabrication de celles-ci
WO2003007889A2 (fr) * 2001-07-17 2003-01-30 Research Development Foundation Agents therapeutiques contenant des proteines pro-apoptotiques
US20030086919A1 (en) * 2001-07-17 2003-05-08 Rosenblum Michael G. Therapeutic agents comprising pro-apoptotic proteins
WO2004096271A1 (fr) * 2003-04-30 2004-11-11 Uwe Zangemeister-Wittke Procedes de traitement de cancer mettant en oeuvre une immunotoxine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LIU YUYING ET AL: "Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. 10 FEB 2004, vol. 108, no. 4, 10 February 2004 (2004-02-10), pages 549 - 557, XP002390486, ISSN: 0020-7136 *
LIU YUYING ET AL: "Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.", MOLECULAR CANCER THERAPEUTICS. DEC 2003, vol. 2, no. 12, December 2003 (2003-12-01), pages 1341 - 1350, XP002390487, ISSN: 1535-7163 *
LYU ET AL.: "Molecular mechanism of a synergistic interaction between scFv23/TNF and f-fluorouracil in L3.6pl", PROC AMER ASSOC CANCER RES, vol. 45, 2004, XP002403628, Retrieved from the Internet <URL:HTTP://WWW.AACRMEETINGABSTRACTS.ORG/CGI/CONTENT/ABSTRACT/2004/1/510-A> [retrieved on 20061018] *
ROSENBLUM M G ET AL: "A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 88, no. 2, 15 October 2000 (2000-10-15), pages 267 - 273, XP002375975, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
RU2007130552A (ru) 2009-02-20
EP1846039A2 (fr) 2007-10-24
CA2593648A1 (fr) 2006-07-13
JP2008526889A (ja) 2008-07-24
CN101203247A (zh) 2008-06-18
US20060263368A1 (en) 2006-11-23
AU2006203850A1 (en) 2006-07-13
WO2006074451A9 (fr) 2007-04-26
WO2006074451A2 (fr) 2006-07-13

Similar Documents

Publication Publication Date Title
WO2006074451A3 (fr) Molecules chimeriques ciblees pour la therapie du cancer
WO2007033023A3 (fr) Compositions et methodes pour le diagnostic et le traitement de cancers associes au gene bcl2
WO2008146911A1 (fr) Anticorps dirigé contre il13ra2 et agent de diagnostic/thérapie comprenant l&#39;anticorps
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
HK1206368A1 (en) Targeting complement factor h for treatment of diseases by the sue of cr2-fh molecules cr2-fh h
WO2007112193A3 (fr) Conjugués de groupements se liant à la camptothécine
WO2008015383A3 (fr) Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer
NZ594746A (en) Inhibitors of iap
NO20075245L (no) Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer
WO2007150077A8 (fr) Immunogènes inducteurs de la production de lymphocytes t cytotoxiques utilisables en vue de la prévention, du traitement et du diagnostic du cancer
WO2009100194A3 (fr) Conjugués à fraction de liaison à la camptothécine
IN2012DN03025A (fr)
WO2007105027A8 (fr) Médicaments anticancéreux conjugués à un anticorps au moyen d&#39;un lieur dissociable par une enzyme
WO2009009173A3 (fr) Klotho bêta
WO2009053038A3 (fr) Polythérapie associant un anticorps anti-cd20 de type ii et un inhibiteur du protéasome
WO2008103920A3 (fr) Cages de protéines ciblées
WO2012138694A3 (fr) Compositions comprenant des fractions de liaison au saccharide et procédés pour une thérapie ciblée
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2008070472A3 (fr) Utilisation de plasma hsp90 lié à une malignité
WO2008144223A3 (fr) Composés triazolyl aminopyrimidine
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l&#39;ovaire
IL191999A0 (en) Targeting gli proteins in human cancer by small molecules
WO2007100920A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2008039994A3 (fr) Agent thérapeutique photodynamique ciblé
GB0502573D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680006202.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006203850

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2593648

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007550561

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006203850

Country of ref document: AU

Date of ref document: 20060110

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6125/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007130552

Country of ref document: RU

Ref document number: 2006733667

Country of ref document: EP